More articles from Endocrinology

You have access
Should I start an SGLT-2 inhibitor in my patient with heart failure and chronic kidney disease?
Richard Sekerak, MD, Johanna Ben-Ami Lerner, MD, Pooja Prasad, MD and Megha Prasad, MD

Cleveland Clinic Journal of Medicine October 2023, 90 (10) 607-609; DOI: https://doi.org/10.3949/ccjm.90a.23004

These conditions often co-exist and can have complex interactions. The progression of kidney disease increases the risk of major adverse cardiovascular events.
You have access
Inpatient glycemic management in noncritically ill patients: Updated guidelines
Michelle D. Lundholm, MD and Oscar L. Morey-Vargas, MD

Cleveland Clinic Journal of Medicine October 2023, 90 (10) 615-618; DOI: https://doi.org/10.3949/ccjm.90a.23049

The guidelines include a role for newer diabetes technologies and nontraditional insulin and noninsulin therapies.